Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Current Challenges and Opportunities in Treating Glioma
share announcement

Current Challenges and Opportunities in Treating Glioma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 1416

Special Issue Editors

Dr. Monika Szeliga

E-Mail Website
Guest Editor
Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland
Interests: cancer; cell cycle; anticancer therapy; proliferation; migration; cell metabolism
Dr. Marta Obara-Michlewska

E-Mail Website
Guest Editor
Department of Neurotoxicology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Pawińskiego 5, 02-106 Warsaw, Poland
Interests: neurotoxicity; astrocyte metabolism

Special Issue Information

Dear Colleagues,

Gliomas are the most frequent primary brain tumors that arise from glial or precursor cells, and include astrocytoma, oligodendroglioma, ependymoma, and mixed glioma. Despite progress in providing key insights into glioma pathogenesis and advances in treatment modalities, glioma remains a uniformly fatal disease. Heterogeneity, glioma stem cells (GSCs), tumor immune microenvironment, delivery of active compounds through the blood–brain barrier, and drug resistance are the leading causes of therapy failure. The awaited breakthrough in glioma treatment requires a multidisciplinary approach, involving further progress in neuroscience research, as well as shifting towards precision medicine, adjusting the clinical protocols according to the neoplasm’s individual genetic background as well as the clinical status of the patient.

This Special Issue intends to collect original research papers and review articles to present contemporary challenges in the diagnosis and management of gliomas, as well as new potential approaches for treating these neoplasms.

Dr. Monika Szeliga
Dr. Marta Obara-Michlewska
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glioma
  • ependymoma
  • oligodendroglioma
  • astrocytoma
  • glioblastoma
  • glioma treatment
  • drug resistance
  • immunotherapy
  • glioma stem cells

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1344 KiB  
Article
Postoperative Communicating Hydrocephalus Following Grade 2/3 Glioma Resection: Incidence, Timing and Risk Factors
by Lisa S. Hönikl, Nicole Lange, Bernhard Meyer, Jens Gempt and Hanno S. Meyer
Cancers 2023, 15(14), 3548; https://doi.org/10.3390/cancers15143548 - 09 Jul 2023
Cited by 1 | Viewed by 951
Abstract
Background: In diffusely infiltrating gliomas, the maximum extent of tumor resection is an important predictor of overall survival, irrespective of histological or molecular subtype or tumor grade. For glioblastoma WHO grade 4 (GBM), it has been shown that resection-related events, such as ventricular [...] Read more.
Background: In diffusely infiltrating gliomas, the maximum extent of tumor resection is an important predictor of overall survival, irrespective of histological or molecular subtype or tumor grade. For glioblastoma WHO grade 4 (GBM), it has been shown that resection-related events, such as ventricular opening and ventriculitis, increase the risk for development of communicating hydrocephalus (CH) requiring cerebrospinal fluid (CSF) diversion surgery. Risk factors for the development and the incidence of hydrocephalus following resection of other types of infiltrating gliomas are less well established. In this study, we evaluated the incidence and timing of occurrence of different types of hydrocephalus and potential risk factors for the development of CH following resection of grade 2 and 3 gliomas. Methods: 346 patients who underwent tumor resection (WHO grade 2: 42.2%; 3: 57.8%) at our department between 2006 and 2019 were analyzed retrospectively. For each patient, age, sex, WHO grade, histological type, IDH mutation and 1p/19q codeletion status, tumor localization, number of resections, rebleeding, ventriculitis, ventricular opening during resection and postoperative CSF leak were determined. Uni- as well as multivariate analyses were performed to identify associations with CH and independent risk factors. Results: 24 out of 346 (6.9%) patients needed CSF diversion surgery (implantation of a ventriculoperitoneal or ventriculoatrial shunt) following resection. Nineteen patients (5.5%) had CH, on median, 44 days after the last resection (interquartile range: 18–89 days). Two patients had obstructive hydrocephalus (OH), and three patients had other CSF circulation disorders. CH was more frequent in grade 3 compared to grade 2 gliomas (8.5 vs. 1.4%). WHO grade 3 (odds ratio (OR) 7.5, p = 0.00468), rebleeding (OR 5.0, p = 0.00984), ventriculitis (OR 4.1, p = 0.00463) and infratentorial tumor localization (OR 6.6, p = 0.00300) were identified as significant independent risk factors for the development of post-resection CH. Ventricular opening was significantly associated with CH, but it was not an independent risk factor. Conclusion: Physicians treating brain tumor patients should be aware that postoperative CH requiring CSF shunting occurs not only in GBM but also after resection of lower-grade gliomas, especially in grade 3 tumors. It usually occurs several weeks after resection. Rebleeding and postoperative ventriculitis are independent risk factors. Full article
(This article belongs to the Special Issue Current Challenges and Opportunities in Treating Glioma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop